Evaluation of Combined Live, Attenuated Respiratory Syncytial Virus and Parainfluenza 3 Virus Vaccines in Infants and Young Children | Zendy

Robert B. Belshe | Zendy; Frances K. Newman | Zendy; Edwin L. Anderson | Zendy; Peter F. Wright | Zendy; Ruth A. Karron | Zendy; Sharon J. Tollefson | Zendy; Frederick W. Henderson | Zendy; H. Cody Meissner | Zendy; Shabir A. Madhi | Zendy; Don Roberton | Zendy; Helen Marshall | Zendy; Richard Loh | Zendy; Peter D. Sly | Zendy; Brian R. Murphy | Zendy; Joanne M. Tatem | Zendy; Valerie B. Randolph | Zendy; Jill Hackell | Zendy; William C. Gruber | Zendy; Theodore F. Tsai | Zendy

Open Access

Evaluation of Combined Live, Attenuated Respiratory Syncytial Virus and Parainfluenza 3 Virus Vaccines in Infants and Young Children

Author(s) -

Robert B. Belshe,

Frances K. Newman,

Edwin L. Anderson,

Peter F. Wright,

Ruth A. Karron,

Sharon J. Tollefson,

Frederick W. Henderson,

H. Cody Meissner,

Shabir A. Madhi,

Don Roberton,

Helen Marshall,

Richard Loh,

Peter D. Sly,

Brian R. Murphy,

Joanne M. Tatem,

Valerie B. Randolph,

Jill Hackell,

William C. Gruber,

Theodore F. Tsai

Publication year - 2004

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/425981

Subject(s) - virology , virus , respiratory system , medicine , paramyxoviridae , attenuated vaccine , pneumovirus , biology , viral disease , virulence , biochemistry , gene

We evaluated a combination respiratory syncytial virus (RSV) and parainfluenza 3 virus (PIV3) live, attenuated intranasal vaccine for safety, viral replication, and immunogenicity in doubly seronegative children 6-18 months old. RSV cpts-248/404 and PIV3-cp45 vaccines were combined in a dose of 10(5) plaque-forming units of each per 0.5-mL dose and compared with monovalent vaccines or placebo. The virus shedding pattern of RSV was not different between monovalent RSV cpts-248/404 vaccine and combination vaccine. Modest reductions in the shedding of PIV3-cp45 vaccine virus were found after the administration of RSV cpts-248/404 and PIV3-cp45 vaccine, relative to monovalent PIV3 vaccine; 16 (76%) of 21 children given combination vaccine shed PIV3-cp45 versus 11 (92%) of 12 of those given monovalent PIV3 vaccine. Both vaccines were immunogenic, and antibody responses were similar between the monovalent groups and the combination group. Combined RSV/PV3 vaccine is feasible for simultaneous administration, and further studies are warranted.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research